Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers

News

Recent Press Releases Archives

Recent Press Releases

2015 News Releases

Dec. 30, 2015 - Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 29, 2015 - Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 23, 2015 - ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 18, 2015 - Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Read

Dec. 16, 2015 - Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea
Read

Dec. 11, 2015 - Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) at the 2015 San Antonio Breast Cancer Symposium
Read

Dec. 10, 2015 - Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium
Read

Dec. 10, 2015 - Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer
Read

Nov. 30, 2015 - Puma Biotechnology Provides Update from Meeting with European Medicines Agency
Read

Nov. 13, 2015 - Puma Biotechnology to Present Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

Nov. 9, 2015 - Puma Biotechnology Reports Third Quarter 2015 Financial Results
Read

Nov. 3, 2015 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

Sept. 26, 2015 - Puma Biotechnology Announces Presentation of Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients
Read

Sept. 10, 2015 - Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation
Read

Aug. 10, 2015 - Puma Biotechnology Reports Second Quarter 2015 Financial Results
Read

June 4, 2015 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference
Read

June 1, 2015 - Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival
Read

May 27, 2015 - Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference
Read

May 13, 2015 - Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Read

May 12, 2015 - Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference
Read

May 11, 2015 - Puma Biotechnology Reports First Quarter 2015 Financial Results
Read

May 6, 2015 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
Read

April 30, 2015 - Puma Biotechnology to Present at Deutsche Bank Health Care Conference
Read

April 14, 2015 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Read

Mar. 10, 2015 - Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Read

Mar. 2, 2015 - Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Read

Feb. 24, 2015 - Puma Biotechnology to Present at Cowen Health Care Conference
Read

Feb. 18, 2015 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare Conference
Read

Feb. 5, 2015 - Puma Biotechnology to Present at Leerink Global Healthcare Conference
Read

Jan. 27, 2015 - Puma Biotechnology Closes $218 Million Public Offering of Common Stock
Read

Jan. 22, 2015 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares
Read

Jan. 21, 2015 - Puma Biotechnology Prices Public Offering of Common Stock
Read

Jan. 20, 2015 - Puma Biotechnology Announces Proposed Public Offering
Read

Jan. 5, 2015 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read




Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax